Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

  • Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
    PR·

    Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

    New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery aloneResults evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026

    $JNJ
  • Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026
    PR·

    Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

    AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand Semtech Corporation (NASDAQ:SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261024697343/en/Semtech’s AirLink XR60, XR80 and XR90 in-vehicle

    $SMTC
  • Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
    PR·

    Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

    Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (NASDAQ:GMAB) and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutati

    $GMAB$INCY
  • Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
    PR·

    Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

    Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Incyte (NASDAQ:INCY) and Genmab A/S (NASDAQ:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation,

    $INCY$GMAB
  • NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
    PR·

    NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

    In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses75% (18/24) disease control rate (DCR)17.8 months median Overall SurvivalExploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatmentInvestigators concluded that these preliminary findings warrant further evaluation in randomized clinical

    $NBTX
  • BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
    PR·

    BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

    Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October

    $ONC
  • Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
    PR·

    Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

    Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases  ORR and median duration of response was 59% and 19.4 months for the gedatolisib triplet and 43% and 27.8 months for the gedatolisib doublet, respectively, compared to 33% and 7.5 months for alpelisib + fulvestrant The discontinuation rate for gedatolisib due to treatment-emergent adverse events was 5% and 4% with the gedatolisib triplet and doublet, respectively, compared to 19% for alpelisib

    $CELC
  • Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
    PR·

    Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

    As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or death.Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate (DCR) was also significantly improved (62.2% vs. 36.8%).A new, post hoc analysis of overall survival (OS) included in the JCO publication uses the Two-Stage Estimation, an established method for adjusting for crossover, and demonstrates an OS hazard ratio of 0.85 (95% CI, 0.59–1.26; p=0.53). Safety profile was consistent with prior tovecimig studies and the anti-VEGF c

    $CMPX
  • Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
    PR·

    Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

    Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levelsClinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapySofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol

    $LLY
  • Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
    PR·

    Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

    IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expressionClinical profile of IMA402 reinforces development path across multiple solid tumor indications, including melanoma, gynecologic cancers and lung cancer, in earlier and later treatment lines, supported by Immatics’ innovative, rapid liquid biopsy-based PRAME testingIMA203CD8 PRAME cell therapy demonstrated deep and durable anti-tumor activity across multiple tumor types with a manageable safety profile, supporting its

    $IMTX
  • Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
    PR·

    Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

    ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levelsConfirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancerMedian duration of response not yet reached at either dose level at median 7 months follow-up, with six-month progression-free survival rate of 61% in both groupsFavorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaborationConference call with Zymeworks management on October 27 at 8:30 am Eastern

    $ZYME
  • Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
    PR·

    Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

    Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologySEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ:SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor mic

    $SMMT
  • RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
    PR·

    RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

    ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight’s common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November 3, 2026. Each inducement stock option has an exercise price of $5.02

    $RXST
  • Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
    PR·

    Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

    FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual endothelin and angiotensin receptor antagonism and support FILSPARI as foundational treatment in IgAN Travere Therapeutics, Inc. (NASDAQ:TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO."These biomarker data provide new ins

    $TVTX
  • Hawaiian Electric Industries to Announce Third Quarter 2026 Results November 6
    PR·

    Hawaiian Electric Industries to Announce Third Quarter 2026 Results November 6

    Hawaiian Electric Industries, Inc. (HEI) (NYSE - HE) will announce its third quarter 2026 financial results on Friday, November 6 and conduct a webcast and conference call to discuss the results at 11:30 a.m. Hawaii time (4:30 p.m. Eastern time). To listen to the conference call, dial 1-833-461-5787 (U.S.) or 1-585-542-9983 (international) and enter passcode 578443699. Parties may also access presentation materials and/or listen to the conference call by visiting the conference call link on HEI’s website at www.hei.com under "Investor Relations," sub-heading "News and Events – Events and Presentations." A replay will be available online and via phone. The online replay will be available

    $HE
  • Club Offers for Travel Enthusiasts in Canada
    PR·

    Club Offers for Travel Enthusiasts in Canada

    Travelzoo® (NASDAQ:TZOO), the club for travel enthusiasts, announces three of many new Club Offers for Club Members in Canada. Rigorously vetted and negotiated for us travel enthusiasts:$799—COSTA RICA WEEK WITH FLIGHTS & CARWe think fall is an ideal time to visit Costa Rica; the scenery is lush and the crowds are gone. Drive between volcanic Arenal and the idyllic beaches of Tamarindo on this seven-night trip. Since it's not as busy, we were able to negotiate a price that saves members up to $648 on departures through mid-December.$899—BARCELONA: 5 NIGHTS WITH FLIGHTSExplore Barcelona's wo

    $TZOO
  • Principal Real Estate Income Fund Announces Changes in Portfolio Management
    PR·

    Principal Real Estate Income Fund Announces Changes in Portfolio Management

    Principal Real Estate Income Fund (the "Fund"), which is traded on the New York Stock Exchange under the symbol "PGZ," announced Marc Peterson will retire from Principal Real Estate Investors, LLC ("PrinREI"), the dedicated real estate investment team of Principal Asset Management®, on October 23, 2026, and will no longer serve as a portfolio manager of the Fund at that time. Kelly Rush, CIO of global real estate securities, will remain as co-portfolio manager of the Fund and, effective October 23, 2026, Laura Rank, managing director and portfolio manager, and Jason Haigh, portfolio manager, will serve as co-portfolio managers. There will be no changes to the Fund’s investment objectives or

    $PGZ$SSNC$PFG
  • Greenberg Traurig Advises SL Green on $2.0 Billion Refinancing of 245 Park Avenue
    PR·

    Greenberg Traurig Advises SL Green on $2.0 Billion Refinancing of 245 Park Avenue

    Global law firm Greenberg Traurig, LLP represented SL Green Realty Corp. (NYSE:SLG), Manhattan's largest office landlord, and its partner, a U.S. affiliate of Mori Trust Co., Ltd, in connection with the $2 billion refinancing of 245 Park Avenue, a Class A office tower in Midtown Manhattan. The deal closed Oct. 14 and marks a major financing milestone for the fully leased tower, which is nearing completion of a comprehensive redevelopment."SL Green and Mori Trust's reimagining of 245 Park Avenue has elevated the building into a true flagship on Park Avenue, and the scale and terms of this

    $SLG
  • Black Rock Coffee Bar Continues Expansion in California with New Rancho Cucamonga Location
    PR·

    Black Rock Coffee Bar Continues Expansion in California with New Rancho Cucamonga Location

    Black Rock Coffee Bar, the Oregon-born boutique coffee chain celebrated for its specialty coffees, teas, smoothies, and signature Fuel® energy drinks, is growing its footprint in California with the opening of a new store in Rancho Cucamonga.  The store, located at 11370 Fourth St, will officially open its doors on Sunday, October 25th. This opening marks Black Rock’s eighth California location and reinforces the brand’s steady expansion across the state. Guests can enjoy the following specials during opening week:  Sunday, October 25th: $2 Medium Drinks  Monday, October 26th: BOGO Drinks  Tuesday, October 27th: 50%

    $BRCB
  • Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering
    PR·

    Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering

    Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Silver Pony Resources Corp. (CSE:PONY) (FSE: BJ40) (OTCID: PONIF) (formerly Carlyle Commodities Corp.) ("Silver Pony" or the "Company") is pleased to announce that, further to its news release dated October 16, 2026, it has up-sized and closed its previously announced non-brokered private placement (the "Offering") of 9,411,852 units of the Company (each, a "Unit") at a price of $0.17 per Unit for total gross proceeds of $1,600,015.Morgan Good, Silver Pony's President and CEO, commented: "Our team is of course thrilled with the interest developing around Silver Pony. Raising approximately $2,900,000 between today's offering c

    $PONY